number of downloads : ?
language
eng
Author
Furukawa , Toshi A. Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Kato , Tadashi Aratama Kokorono Clinic, Nagoya, Japan
Shinagawa, Yoshihiro Shiki Clinic, Nagoya, Japan
Miki, Kazuhira Miki Mental Clinic, Yokohama, Japan
Fujita, Hirokazu Center to Promote Creativity in Medical Education, Kochi Medical School, Kochi University, Nankoku, Japan
Tsujino, Naohisa Department of Neuropsychiatry, Toho University School of Medicine, Tokyo, Japan
Kondo, Masaki Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Yamada, Mitsuhiko Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Tokyo, Japan
Subject
Major depression; pharmacotherapy; prediction model; remission
Journal Title
PSYCHOLOGICAL MEDICINE
Volume
49
Issue
14
Start Page
2405
End Page
2413
ISSN
0033-2917
ISSN(Online)
1469-8978
Published Date
2019-10
DOI
PubMed ID
Publisher
CAMBRIDGE UNIV PRESS
NII Type
Journal Article
OAI-PMH Set
Faculty of Medicine
Remark
The study was funded by the Ministry of Health, Labor and Welfare, Japan (H-22-Seishin-Ippan-008) from April 2010 through March 2012 to TAF (http://www.mhlw.go.jp/english/), and thereafter by the Japan Foundation for Neuroscience and Mental Health (JFNMH) to TAF (http://www.jfnm.or.jp/). The JFNMH received donations from Asahi Kasei, Eli Lilly, GSK, Janssen, MSD, Meiji, Mochida, Otsuka, Pfizer, Shionogi, Taisho, and Mitsubishi-Tanabe. The study is partly supported by Japan Agency for Medical Research and Development (18dk0307072) and the Ministry of Health, Labour and Welfare (H29-ICT-Ippan-010). The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.